Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    melanoma,cancer,PARP
Show Display Options
Rank Status Study
1 Completed A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
Condition: Melanoma Neoplasms
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor);   Drug: dacarbazine
2 Completed An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
3 Not yet recruiting Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes
Conditions: Advanced Solid Neoplasm;   Aggressive Non-Hodgkin Lymphoma;   Recurrent Solid Neoplasm;   Refractory Mantle Cell Lymphoma;   T-Cell Non-Hodgkin Lymphoma;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study;   Drug: Veliparib
4 Not yet recruiting Nivolumab in Prostate Cancer With Mutations in DNA Repair Defects (ImmunoProst Trial)
Condition: Prostate Cancer
Intervention: Drug: Nivolumab
5 Completed A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
Conditions: Non-hematologic Malignancies;   Metastatic Melanoma;   Breast Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Hepatocellular Carcinoma
Interventions: Drug: ABT-888;   Drug: Temozolomide
6 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Carcinoma;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
7 Terminated A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: INO-1001;   Drug: temozolomide

Study has passed its completion date and status has not been verified in more than two years.